Literature DB >> 17382262

Molecular genetics of neuroendocrine tumors.

Eva-Maria Duerr1, Daniel C Chung.   

Abstract

Neuroendocrine tumors can develop either sporadically or in association with familial syndromes such as multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2) or von Hippel-Lindau (VHL). A variety of genetic approaches has been utilized to dissect the underlying molecular pathogenesis of these distinctive tumors, including genome-wide screens such as comparative genomic hybridization, loss of heterozygosity and DNA microarray analysis as well as targeted investigations into specific tumor suppressor gene and oncogene candidates. The identification of the MEN1 tumor suppressor gene that underlies the MEN1 syndrome has provided important new insights into tumor pathogenesis. In addition, a number of independent approaches has converged on a pivotal role for regulators of the cell cycle. However, our understanding of the molecular biology of these tumors remains far from complete. In this review we highlight some of the key approaches, findings and implications of these genetic studies.

Entities:  

Mesh:

Year:  2007        PMID: 17382262     DOI: 10.1016/j.beem.2006.12.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  16 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.

Authors:  Wenwei Hu; Zhaohui Feng; Ippolito Modica; David S Klimstra; Lin Song; Peter J Allen; Murray F Brennan; Arnold J Levine; Laura H Tang
Journal:  Genes Cancer       Date:  2010-05-15

3.  Gastric carcinoids: between underestimation and overtreatment.

Authors:  Sara Massironi; Valentina Sciola; Matilde-Pia Spampatti; Maddalena Peracchi; Dario Conte
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

4.  VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis.

Authors:  Scott R Silva; Kanika A Bowen; Piotr G Rychahou; Lindsey N Jackson; Heidi L Weiss; Eun Y Lee; Courtney M Townsend; B Mark Evers
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

Review 5.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 6.  Neuroendocrine tumors of the gastro-entero-pancreatic system.

Authors:  Sara Massironi; Valentina Sciola; Maddalena Peracchi; Clorinda Ciafardini; Matilde Pia Spampatti; Dario Conte
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

7.  Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases.

Authors:  Nicole Posorski; Daniel Kaemmerer; Guenther Ernst; Patricia Grabowski; Dieter Hoersch; Merten Hommann; Ferdinand von Eggeling
Journal:  Clin Exp Metastasis       Date:  2011-06-17       Impact factor: 5.150

8.  Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.

Authors:  Sunita K Agarwal; Carmen M Mateo; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

Review 9.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

Review 10.  Zollinger-Ellison syndrome: recent advances and controversies.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Curr Opin Gastroenterol       Date:  2013-11       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.